CPS Technologies Corporation

CPS Technologies Schedules Its Q2 Earnings Call

2026-07-31 16:30:00

NORTON, Mass., July 31, 2026 (GLOBE NEWSWIRE) -- CPS Technologies Corp. (Nasdaq:CPSH) today released instructions for its second quarter 2026 investor conference call which will be held on Wednesday August 5, 2026 at 9:00 A.M. (Eastern). Brian Mackey, President and CEO and Chris Fraser, Chief Financial Officer will discuss the Company's financial results for the quarter ended June 27, 2026.

Analyzing CPS Technologies (NASDAQ:CPSH) & Allient (NASDAQ:ALNT)

2026-07-30 01:59:03

CPS Technologies (NASDAQ: CPSH - Get Free Report) and Allient (NASDAQ: ALNT - Get Free Report) are both small-cap computer and technology companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, risk, valuation, dividends and profitability. Insider and Institutional Ownership 11.2% of

CPS Announces $716.88 Million Senior Subordinate Asset-Backed Securitization

2026-07-22 13:34:00

LAS VEGAS, Nevada, July 22, 2026 (GLOBE NEWSWIRE) -- Consumer Portfolio Services, Inc. (Nasdaq: CPSS) (“CPS” or the “Company”) announced the closing of its third term securitization in 2026 on Wednesday July 22, 2026. This is the largest securitization in the history of the company. The transaction is CPS's 60th senior subordinate securitization since the beginning of 2011 and the 43rd consecutive securitization to receive a triple “A” rating from at least two rating agencies on the senior class of notes.

OSI Systems (NASDAQ:OSIS) and CPS Technologies (NASDAQ:CPSH) Head-To-Head Review

2026-07-22 01:15:18

OSI Systems (NASDAQ: OSIS - Get Free Report) and CPS Technologies (NASDAQ: CPSH - Get Free Report) are both computer and technology companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations. Earnings and Valuation This table compares

CPS Announces Renewal And Capacity Increase Of Credit Facility

2026-07-09 16:19:00

LAS VEGAS, July 09, 2026 (GLOBE NEWSWIRE) -- Consumer Portfolio Services, Inc. (Nasdaq: CPSS) (“CPS” or the “Company”) today announced that on July 9, 2026, it renewed its two-year revolving credit agreement with Citibank, N.A. while simultaneously increasing the capacity of the facility. The renewal and increase apply to both Citibank, N.A. and the subordinate lender, and increases the capacity of the facility from $335 million to $508 million.

Rush Gold Provides Update Regarding Private Placement, Announces Advisory Agreement and Announces Proposed Acquisition of Landy Investments

2026-06-30 09:00:00

VANCOUVER, BC – TheNewswire - June 30, 2026 – Rush Gold Corp. (“Rush” or the “Company”) (CSE: RGN | OTCQB: RGNCF | FSE: B6H) is pleased to announce, further to its news releases dated March 11, 2026 and April 17, 2026, that it remains focused on completing its previously announced private placement of common shares (“ Shares ”) at a price of $0.10 per Share (the “ Private Placement ”). The Company is also pleased to announce that it has entered into a corporate advisory agreement (the “ Advisory Agreement ”), dated June 29, 2026, with CPS Capital Group Pty Ltd (“ CPS Capital ”), a Perth-based corporate advisory firm, to act as the Company's exclusive Australian Lead Manager, Broker and Corporate Advisor for capital raising and corporate advisory services. In addition, the Company is pleased to announce that it has entered into a share purchase agreement (the “ Landy Agreement ”), dated June 29, 2026, to acquire all of the issued and outstanding shares of Landy Investments Ltd. (“ Landy ”), a private British Columbia company that holds rights to acquire mining claims in Nevada, USA (the “ Landy Acquisition ”).   Private Placement

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)

2026-06-25 06:45:00

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each in combination with Trodelvy® (sacituzumab govitecan-hziy), Gilead's Trop-2-directed antibody-drug conjugate (ADC), for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative.

CPS Technologies Corp. Announces Pricing of $9.6 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

2026-05-28 08:00:00

NORTON, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- CPS Technologies Corp. (NASDAQ: CPSH) (“CPS” or the “Company”), today announced that it has entered into definitive securities purchase agreements with certain institutional investors for the purchase and sale of an aggregate of 1,200,000 shares of the Company's common stock at a purchase price of $8.00 per share in a registered direct offering priced at-the-market under Nasdaq rules.